Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.

Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S.

Neurobiol Aging. 2004 Mar;25(3):311-4.

PMID:
15123336
2.

Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.

Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):633-44.

PMID:
10669911
3.

Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.

Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S.

Neurobiol Aging. 2006 Mar;27(3):451-8.

PMID:
15964100
4.

Hypometabolism as a therapeutic target in Alzheimer's disease.

Costantini LC, Barr LJ, Vogel JL, Henderson ST.

BMC Neurosci. 2008 Dec 3;9 Suppl 2:S16. doi: 10.1186/1471-2202-9-S2-S16. Review.

5.

Impact of APOE in mild cognitive impairment.

Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC.

Neurology. 2004 Nov 23;63(10):1898-901.

PMID:
15557508
6.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
7.

Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.

Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ.

J Clin Psychiatry. 2009 Oct;70(10):1379-84. doi: 10.4088/JCP.08m04593.

PMID:
19573495
8.

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study..

Neurology. 2007 May 8;68(19):1588-95.

PMID:
17287448
9.

Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype.

Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ.

Psychoneuroendocrinology. 2003 Aug;28(6):809-22.

PMID:
12812866
10.

Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults.

Pomara N, Willoughby L, Wesnes K, Greenblatt DJ, Sidtis JJ.

Arch Gen Psychiatry. 2005 Feb;62(2):209-16.

PMID:
15699298
11.

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.

Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1538-44. doi: 10.1016/j.pnpbp.2008.05.015.

PMID:
18573585
12.

Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment.

Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S.

Neurology. 2005 Jun 28;64(12):2063-8.

PMID:
15985573
13.

Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4.

Burkhardt MS, Foster JK, Laws SM, Baker LD, Craft S, Gandy SE, Stuckey BG, Clarnette R, Nolan D, Hewson-Bower B, Martins RN.

J Alzheimers Dis. 2004 Jun;6(3):221-8.

PMID:
15201477
14.

AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R.

Neurology. 2007 Mar 27;68(13):1008-12.

PMID:
17389305
15.

Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.

Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):201-6.

PMID:
12212781
16.

Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S.

Neurology. 2008 Feb 5;70(6):440-8. Erratum in: Neurology. 2008 Sep 9;71(11):866.

PMID:
17942819
17.

"Brain-specific" nutrients: a memory cure?

McDaniel MA, Maier SF, Einstein GO.

Nutrition. 2003 Nov-Dec;19(11-12):957-75. Review.

PMID:
14624946
18.

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S.

Am J Geriatr Psychiatry. 2005 Nov;13(11):950-8.

PMID:
16286438
19.

Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment.

Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study..

Arch Neurol. 2005 Jun;62(6):953-7.

PMID:
15956166
20.

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.

Pomara N, Ott BR, Peskind E, Resnick EM.

Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):60-4.

PMID:
17334274
Items per page

Supplemental Content

Support Center